Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT06591299Phase 3Recruiting
Phase 3, randomised, single-blind trial in ischemic stroke and Transient Ischemic Attack (TIA) comparing cilostazol and aspirin with clopidogrel and aspirin (2 arms). Primary endpoints: Rate of new stroke at 90 days and Rate of drug-related hemorrhagic complications at 90 days. Started Apr 2022; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT06591299.